HCW Biologics Stock (NASDAQ:HCWB)

Revenue Ownership Financials Chart

Previous Close

$0.41

52W Range

$0.28 - $2.52

50D Avg

$0.50

200D Avg

$0.85

Market Cap

$16.98M

Avg Vol (3M)

$9.36M

Beta

0.84

Div Yield

HCWB Company Profile

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jul 20, 2021

Website

HCWB Performance

HCWB Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$2.84M	$6.72M	-
Operating Income	$-25.72M	$-15.08M	$-13.37M
Net Income	$-24.99M	$-14.72M	$-12.36M
EBITDA	$-24.58M	$-14.77M	$-12.82M
Basic EPS	$-0.70	$-0.41	$-0.35
Diluted EPS	$-0.70	$-0.41	$-0.35

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
IPSC	Century Therapeutics, Inc.
PMVP	PMV Pharmaceuticals, Inc.
MNOV	MediciNova, Inc.
CSBR	Champions Oncology, Inc.
RZLT	Rezolute, Inc.
PEPG	PepGen Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
STTK	Shattuck Labs, Inc.
PHVS	Pharvaris N.V.
MOLN	Molecular Partners AG